ArticleAmerican journal of respiratory and critical care medicine2011
Risk factors for chronic kidney disease in adults with cystic fibrosis.
Article in American journal of respiratory and critical care medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06595420 (Kidney Function in People With Cystic Fibrosis in the Era of HEMT), which is not on this map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Kidney Function in People With Cystic Fibrosis in the Era of HEMT
Who cites it
34 citing papers in PubMed, 88 citations in OpenAlex.
- A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment.American journal of respiratory and critical care medicine · 2021Trial
- Long-term effectiveness and safety of cystic fibrosis transmembrane conductance regulator modulators and their impact on the lives of people with cystic fibrosis.American journal of respiratory and critical care medicine · 2026Article
- Kidney Failure in Persons With Cystic Fibrosis.Kidney medicine · 2026Article
- Risk factors for longitudinal estimated glomerular filtration rate decline in adults with cystic fibrosis.Annals of the American Thoracic Society · 2026Article
- Cystic fibrosis-related kidney disease-emerging morbidity and disease modifier.Pediatric nephrology (Berlin, Germany) · 2025Review
- Screening and monitoring across the lifespan of an ageing cystic fibrosis population.ERJ open research · 2025Review
- Diagnosis and Emerging Biomarkers of Cystic Fibrosis-Related Kidney Disease (CFKD).Journal of clinical medicine · 2025Review
- Patients With Cystic Fibrosis Undergoing Posterior Lumbar Fusion Are at an Increased Odds of Perioperative Complications.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2025Article
- Lung-kidney axis in cystic fibrosis: Early urinary markers of kidney injury correlate with neutrophil activation and worse lung function.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2025Article
- Imaging of cystic fibrosis manifestations in the abdomen.Abdominal radiology (New York) · 2025Review
- A dramatic decline in lung transplantation for cystic fibrosis in the United States.CHEST pulmonary · 2024Article
- The ageing of people living with cystic fibrosis: what to expect now?European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Lung-Kidney Axis in Cystic Fibrosis: Early Urinary Markers of Kidney Injury Correlate with Neutrophil Activation and Worse Lung Function.medRxiv : the preprint server for health sciences · 2024Article
- Clinicopathologic Features of Kidney Disease in Patients With Cystic Fibrosis.Kidney international reports · 2024Article
- Identification of prognostic biomarkers for antibiotic associated nephrotoxicity in cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2024Article
- Cystic fibrosis survival outcomes following second lung transplant: The north American experience.Clinical transplantation · 2023Article
- ISPAD Clinical Practice Consensus Guidelines 2022: Management of cystic fibrosis-related diabetes in children and adolescents.Pediatric diabetes · 2022Article
- Renal Function in Patients with Cystic Fibrosis: A Single-Center Study.International journal of environmental research and public health · 2022Article
- Defining the Importance of Age-Related Changes in Drug Clearance to Optimizing Aminoglycoside Dosing Regimens for Adult Patients with Cystic Fibrosis.European journal of drug metabolism and pharmacokinetics · 2022Article
- Kidney and combined kidney and pancreas transplantation may be under-utilized in cystic fibrosis.Frontiers in transplantation · 2022Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
Abstract
rationaleAdults with cystic fibrosis (CF) possess multiple potential risk factors for chronic kidney disease, including CF-related diabetes (CFRD) and lifetime nephrotoxic drug exposure.
objectivesTo determine whether cumulative intravenous (IV) aminoglycoside exposure and CFRD increase the risk of chronic kidney disease in adults with CF.
methodsThis was a cohort study using adults (≥ 18 yr) in the CF Foundation registry from 2001-2008. Chronic kidney disease (stage 3 or greater) was defined by an estimated glomerular filtration rate of less than 60 ml/min/1.73 m(2). Time-dependent multivariable Cox proportional hazards models were used to determine whether cumulative number of acute pulmonary exacerbations (surrogate for IV aminoglycoside exposure) and CFRD requiring insulin increase the risk of chronic kidney disease, adjusting for confounders. MEASUREMENTS AND MAIN
resultsThe study cohort included 11,912 adults with a median follow-up of 4 years. During the study period, 204 subjects had chronic kidney disease, with an annual disease prevalence of 2.3%. Disease prevalence doubled with every 10-year increase in age. CFRD requiring insulin therapy substantially increased the risk of chronic kidney disease (1-4 yr of CFRD requiring insulin vs. no CFRD, hazard ratio [HR] = 2.40, 95% confidence interval [CI] 1.74-3.32; ≥ 5 yr, HR = 4.56, 95% CI 2.84-7.31). Pulmonary exacerbations did not significantly increase the risk of chronic kidney disease (one to five exacerbations vs. none, HR = 0.79, 95% CI 0.56-1.11; six to nine exacerbations, HR = 0.92, 95% CI 0.58-1.46; ≥ 10 exacerbations, HR = 1.16, 95% CI 0.75-1.81).
conclusionsCF-related diabetes is a significant risk factor for chronic kidney disease in adults with CF, but additional studies examining IV aminoglycoside exposure directly are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.